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Purpose: To evaluate the effect of N-acetylcysteine (NAC) and glutathione ethyl ester (GSH-EE) eye drops on the
progression of diabetic cataract formation induced by streptozotocin (STZ).
Methods: One hundred and thirty Sprague-Dawley (SD) rats were selected, and diabetes was induced by streptozotocin
(65 mg/kg bodyweight) in a single intraperitoneal injection. The control group (group I) received only vehicle. Then, 78
rats with random blood glucose above 14 mmol/l were divided into four groups (group II-V). The drug-treated rats received
NAC and GSH-EE eye drops five days before STZ injection. Group I and V animals received sodium phosphate buffer
drops (pH 7.4), and those in groups II, III, and IV received 0.01% NAC, 0.05% NAC, and 0.1% GSH-EE drops,
respectively. Lens transparency was monitored with a slit lamp biomicroscope and classified into six stages. At the end
of four weeks, eight weeks, and 13 weeks, animals were killed and components involved in the pathogenesis of diabetic
cataract including thiols (from glutathione and protein), glutathione reductase (GR), catalase (CAT), and glycated proteins
were investigated in the lens extracts. Blood glucose, urine glucose, and bodyweight were also determined.
Results: The progression in lens opacity induced by diabetes showed a biphasic pattern in which an initial slow increase
in the first seven weeks after STZ injection was followed by a rapid increase in the next six weeks. The progression of
lens opacity in the treated groups (group II-IV) was slower than that of the untreated group (group V) in the earlier period
and especially in the fourth week. There were statistically significant differences between the treated groups and the
untreated group (p<0.05). However, these differences became insignificant after the sixth week, and the progression of
lens opacification in all diabetic groups became aggravated. The content of thiol (from glutathione and protein), glutathione
reductase (GR), and catalase (CAT) were lower in the lens extracts of the diabetic rats four weeks, eight weeks, and 13
weeks after the STZ injection while the levels of thiol and CAT activity were both higher in the treated groups (group II-
IV) than in the untreated group (group V) at every stage. However, there was no statistically significant difference (p>0.05).
Moreover, the diabetes resulted in an increased level of glycated proteins in both the treated groups and the untreated
group, but there was no statistically significant difference between all the diabetic groups (p>0.05).
Conclusions: NAC and GSH-EE can slightly inhibit the progression of the diabetic cataract at the earlier stage. They may
maintain lens transparency and function by serving as a precursor for glutathione biosynthesis and by protecting sulfhydryl
groups from oxidation.
Understanding the mechanisms of the development of
cataract and looking for available therapeutic methods are
problems of scientific and social interest because cataract is
one of the major causes of reversible blindness. It is estimated
that over 50 million people worldwide suffer from cataracts,
and  the  problem  will  grow  in  parallel  with  aging  of  the
population  [1,2].  At  present,  the  cure  for  cataract  is  still
surgery. However, surgery is not equally available to all, and
where it is available, it does not produce equal outcomes [2,
3]. In addition, risk and cost factors also drive the study of
pharmaceutical  approaches  to  the  maintenance  of  lens
transparency.
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The role of oxidative stress in diseases including diabetes
and the many changes in the development of cataracts is
controversial  [4,5].  The  reducing  compound  glutathione
(GSH),  quantitatively  the  most  important  endogenous
rechargeable  antioxidant,  exists  in  an  unusually  high
concentration in the lens where it functions as an essential
antioxidant vital for maintenance of the tissue’s transparency
[6-8]. The GSH system plays a key role in the protection
against oxidative stress. Depletion of GSH is found in many
cataractous lenses [1,4,7,9,10]. The depletion of GSH or the
inhibition of the redox cycle allows low levels of oxidant to
damage lens epithelial targets such as Na/K-ATPase, certain
cytoskeletal proteins, and proteins associated with normal
membrane  permeability.  In  addition,  GSH  has  several
important functions related to amino acid transport across
membranes,  protein  synthesis  and  degradation,  gene
Molecular Vision 2008; 14:862-870 <http://www.molvis.org/molvis/v14/a103>
Received 17 November 2007 | Accepted 14 April 2008 | Published 12 May 2008
© 2008 Molecular Vision
862regulation, and cellular redox regulation [7,11,12]. Therefore,
supplementation of GSH to the lens may help to maintain its
protective ability against oxidative stress and other attacks and
lead to a slower age-related loss of antioxidant activity of lens
and eventually to delay the onset of cataract [3].
Since by itself GSH is not effectively transported into
cells, several alternatives to increase intracellular levels of
GSH have been developed [12-17]. These alternatives include
N-acetylcysteine (NAC) and GSH esters to boost GSH in the
cell [18]. GSH esters are hydrolyzed to GSH in cells. NAC is
hydrolyzed to cysteine in the cell. It is the availability of
cysteine that usually limits GSH synthesis. NAC limits protein
carbonyl formation in incubated rabbit lens epithelium [19].
NAC,  GSH  monoester,  and  glutathione  isopropyl  ester
injected  intraperitoneally  were  effective  in  delaying  or
preventing  cataract  formation  induced  by  X-irradiation  or
buthionine sulphoxide [14,15]. NAC can combine with other
anti-cataract  drugs  to  prevent  the  progression  of  lens
opacification  [20,21].  The  potential  benefit  of
supplementation  with  NAC  and/or  GSH  ester  in  the
prevention of the development of cataract among the diabetic
population is clear [19].
GSH esters have shown considerable merit following the
inhibition of GSH synthesis and in the reversal of low GSH
in several pathological and clinical conditions requiring high
levels  of  tissue  GSH  [22].  The  ester  is  converted
intracellularly  into  GSH  [13].  GSH  ester  can  prevent
buthionine sulfoximine-induced cataracts and lens epithelial
cell damage [14]. Moreover, γ-glutamylcysteine ethyl ester is
able  to  inhibit  L-buthionine  sulfoximine-induced  cataract
formation by mitigating the deprivation of glutathione and by
elevating the level of glutathione in cultured lens [23]. GSH
ethyl  ester  (GSH-EE)  supplementation  of  mice  improved
endurance  performance  and  prevented  muscle  lipid
peroxidation  by  altering  glutathione  homeostasis  during
prolonged exercise [16]. The antioxidative effect of NAC and
GSH esters had been demonstrated from many studies in vivo
[24,25] and in vitro [17,26]. They made great contributions to
research on the biologic effects and medical application of
NAC and GSH esters.
However,  the  researches  above  were  performed  with
difficulty  for  the  drugs  were  administrated  orally  [27]  or
intraperitoneally [28], and there were many complications
[18,29]. If a drug therapy is to be developed for cataract, it
must  be  extremely  safe  because  a  successful  surgical
procedure is already available. Use of eye drops would avoid
potential systemic complications. The streptozotocin (STZ)-
induced  cataract  model  in  rats  has  been  widely  used
successfully for cataract studies [30,31]. We previously used
the  streptozotocin  (STZ)-induced  cataract  model  in  rats
successfully to assess aspirin, paracetamol, and ibuprofen as
anti-cataract drugs [32]. In the present study, NAC and GSH-
EE eye drops were used for the first time in a STZ-induced
cataract study. The aim of the present study was to investigate
the effect of treatment with NAC and GSH-EE eye drops on
the  development  of  streptozotocin-induced  cataract  in
diabetic rats.
METHODS
Materials:  Streptozotocin  (STZ),  N-acetylcysteine  (NAC),
glutathione  ethyl  ester  (GSH-EE),  and  5-
hydroxymethylfurfural (5-HMF) were purchased from Sigma
Chemical Company (Beijing, China). Sprague-Dawley rats
were provided by Animal Laboratories of Fourth Military
Medical  University  (Xi’an,  China).  Protein  and  enzyme
quantification  kits  were  obtained  from  Jiancheng  Biology
Company (Nanjing, China). Glucotrend 2 was from Roche
Diagnostic Limited Company (Xi’an, China). Tes-Tape was
from Zhujiang Biochemistry Reagents (Guangzhou, China).
All other chemicals and solvents were of analytical grade and
were obtained from local companies.
Experimental design: The experiments lasting over 13 weeks
were performed using Sprague-Dawley rats (obtained from
the  Laboratory  Animal  Research  Centre,  Fourth  Military
Medical University, Xi’an, China), which were housed in
individual polypropylene breeding cages under a day/night
cycle of 12 h at 20–25 °C room temperature. All animals had
unlimited access to water. Animal care and protocols were in
accordance with and approved by the Institutional Animals
Ethics Committee and conformed to the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research.
All the lenses were examined by slit lamp microscopy
before induction of diabetes, and those with any defect of lens
or cornea were rejected. Ten rats were randomly selected for
the  normal  group  (group  I),  and  120  others  were  single
injected intraperitoneally, avoiding the intestine, with STZ
(65  mg/kg  bodyweight),  which  was  dissolved  in  20  mM
sodium citrate buffer, pH 4.5 (10 mg STZ/ml citrate buffer)
after the pH value was adjusted to 7.4. The STZ solution was
sterilized through a 0.22 µM Millipore filter into a sterilized
container kept on ice and used within 10 min of dissolving.
The normal control group (group I), the non-diabetic rats,
were injected with a sterilized buffer. After three days the
blood of each rat was tested for glucose by using Glucotrend
(Roche Company, Germany). The urine of each rat was tested
for glucose with Tes-Tape at the same time. Any STZ-injected
rat that had no detectable glucose in the urine was rejected
(about 35% of those injected). Fasting blood glucose was then
measured in all rats to confirm that the streptozotocin-injected
rats were diabetic (more than 14 mmol/l) and that the control
rats were not. Then, the diabetic rats were divided into four
groups. Seventy-eight diabetic rats were divided into four
groups (group II-V) and received 0.01% NAC drops (group
II; n=19), 0.05% NAC drops (group III; n=19), 0.1% GSH-
EE drops (group IV; n=19). The untreated diabetic group
constituted group V (n=21). The rats were weighed, and five
groups  (group  I-V)  were  established  with  a  comparable
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863weight  distribution  (ranging  from  130.0±27.24  g  to
142.8±27.91 g; p>0.05). There was no significant difference
in weight among these groups.
Preparation of eye drops: The drugs (0.01 g and 0.05 g of
NAC) were dissolved in 100 ml of sodium phosphate buffer
(pH 7.4). After vibration, drugs were completely dissolved
with the pH value of 0.01 g and 0.05 g of NAC drops were 7.4
and  7.1,  respectively.  Five  milligrams  of  GSH-EE  was
dissolved in 5 ml of sodium phosphate buffer solution (pH
7.4). The pH value of the GSH-EE solution was adjusted to
7.2 before use.
Five days before the rats were injected with STZ, all rats
except the normal group were treated with NAC or GSH-EE
drops twice daily. The eye drops were tested for safety and
utility by preliminary experiments. There was no significant
statistical difference between the eyes of drug-treated rats and
untreated rats when observed for irritation and conjunctiva
congestion. The drug solutions were made fresh daily and
preserved in a 4 °C icebox. During dropping, the rats were
held by assistants, and their eyelids were held open. Drops,
two at a time, were administered, and rats were continuously
held for another 2–3 min with light massage of the eyeball to
sustain the volume dose. Initially, the rats were sensitive to
this dropping but became calm after few days of experience.
The rats were fed with standard chow ad libitum.
Slit lamp examination and cataract classification: Eyes were
examined every week using a slit lamp biomicroscope (Haag-
Streit  BQ  900  model;  Hagg-Streit  International,  Koeniz,
Switzerland) on dilated pupils. Initiation and progression of
lenticular  opacity  was  assessed  according  to  the  Oxford
system [32]: grade 0, clear; grade 1, clear nuclear with wide
sutures; grade 2, slight dense nuclear with opacities radiating
from sutures; grade 3, dense nuclear without clefts; grade 4,
dense nuclear with clefts; grade 5, nuclear cataract with clefts;
grade 6, nuclear cataract with dense radial opacities; and grade
7, nuclear cataract with whole lens opacities (Figure 1). The
stage of cataract was scored according to the classification
described above.
Lens preparation: On the 4th, 8th, and 13th week, animals
selected  randomly  from  each  group  were  sacrificed  by
decapitation and their eyeballs were removed for biochemical
evaluation.  Eyeballs  were  soaked  in  0.9%  neutral  normal
saline, and the lenses were dissected by the posterior approach
then placed into pre-weighed Eppendorf tubes and frozen at
–40 °C until further analysis. On the fourth and eighth week,
4, 6, 6, 6, and 6 lenses were used in groups I, II, III, IV and V,
respectively, as well as 10, 12, 10, 12, and 10 lenses on the
13th week, respectively.
Protein determination: Protein concentration was determined
by Coomassie brilliant blue method using protein assay kit
from Jiancheng Company (Nanjing, China).
All lenses were ground in 0.9% neutral normal saline
(1:19) and homogenized and then centrifuged in Eppendorf
tubes. A clear supernatant was used for protein determination,
which was according to the method described with the kits.
Thiol determination: Thiols were measured using the dithio-
bis-nitrobenzoic acid (DTNB) method at 25 °C and 412 nm
[33,34].  The  clear  supernatant  liquid  used  for  protein
determination  was  taken  by  suction  from  the  centrifuged
Eppendorf  tube,  and  the  thiol  content  was  determined
according to the description of the kit. Thiols react with dithio-
bis-nitrobenzoic acid to give a yellow compound that has a
Figure 1. The photograph of all grading lens at the slit lamp (Haag-
Streit BQ 900). The grades are as follows: grade 0, clear; grade 1,
clear nuclear with wide sutures; grade 2, slight dense nuclear with
opacities radiating from sutures; grade 3, dense nuclear without
clefts; grade 4, dense nuclear with clefts; grade 5, nuclear cataract
with clefts; grade 6, nuclear cataract with dense radial opacities; and
grade 7, nuclear cataract with whole lens opacities.
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864high  absorption  of  light  at  412  nm.  This  absorption  was
measured. Through this colorimetric method, the content of
thiol in each lens (from GSH and protein) was measured.
Assay of glutathione reductase activity: Glutathione reductase
(GR) activity was measured according to the procedure of
Linetsky et al. [35]. The reaction was initiated by the addition
of 20 μl of lens homogenate. Oxidized glutathione (GSSG)
was reduced to GSH catalyzed by GR with NADPH as a
cofactor. The decrease in the optical density at 340 nm was
recorded at 25 °C for 2 min. The units of enzymatic activity
were calculated using an extinction coefficient of 6.22 mM/
cm for NADPH. One unit was equivalent to the oxidation of
1 mmol of NADPH per min.
Assay of catalase activity: Catalase (CAT) activity in the lens
was assayed with hydrogen peroxide as the substrate using a
method  based  on  the  direct  measurement  of  H2O2
decomposition [36]. The final volume of each enzyme assay
was 3 ml of substrate and 20 μl of the supernatant of lens
homogenate. The assay was performed at 25 °C and at 240
nm.  Enzyme  activity  was  expressed  as  units  per  gram  of
protein, and one unit of CAT activity represented 1 mmol
H2O2 decomposed per min.
Assay of glycation of lens proteins: The determination of the
amount  of  glycation  of  lens  proteins  was  based  on  the
thiobarbituric  acid  method  [37].  The  5-
hydroxymethylfurfural (5-HMF) was released into solution
on boiling glycated protein in the presence of a weak acid.
Any solubilized protein was then precipitated out of solution
by centrifugation. Thiobarbituric acid forms an adduct with
5-HMF that absorbs at 443 nm. The value was expressed as
units (mmoles HMF per mole protein).
Statistical analysis: One-way ANOVA was used for testing
statistical  significance  between  groups.  The  median
calculation of the lens opacity for each group was analyzed
by using the Wilcoxon rank sum test. p<0.05 was considered
significant. All the data were dealt by the SPSS 11.0 statistical
package.
RESULTS
Blood glucose after injection of streptozotocin: Ten rats were
selected for the normal group, and the others (120 rats) were
injected with STZ. Based on the level of plasma glucose, the
120 rats were designated as non-diabetic rats (<14 mmol/l
plasma  glucose)  and  diabetic  rats  (>14  mmol/l  plasma
glucose).
Based on the monitoring of blood glucose over 72 h, we
found that random blood glucose testing was more reliable to
identify diabetic rats than fasting blood glucose measurement.
About  65.0%  (78/120)  of  the  rats  responded  to  the  STZ
injection (blood glucose>14 mmol/l) according to the random
blood glucose testing. Two weeks after the rats were made
diabetic, three rats were rejected because the blood glucose
had fallen below 14 mmol/l (one rat was from group II and
two rats were from group V). Therefore, all the data of these
rats were excluded from the statistical analysis. Then, 75 rats
in the treated groups were used for statistical analysis.
The diabetic rats had a much higher blood glucose level
than  the  control  rats  throughout  the  experimental  period
(Table  1).  There  was  no  significant  difference  in  blood
glucose  levels  between  the  four  groups  of  diabetic  rats
(p>0.05; Table 1). Treatment with either NAC or GSH-EE did
not reverse the changes in blood glucose, showing that the
NAC and GSH-EE treatment had no effect on hyperglycemia.
The changes of rat’s weights: In all five groups, weight was
gained in a biphasic manner, an initial steep increase for the
first six weeks, followed by a slower change during the next
seven weeks (Figure 2). The diabetic rats had lower weight
gain compared with the normal rats during the experimental
period  (p<0.05;  Figure  2).  In  the  normal  group,  the
bodyweight increased quickly. On the other hand, there were
only slight increases in the other four diabetic groups with a
plateaued weight of about 200 g. There was no statistically
significant difference in the weight gain among the groups of
diabetic rats (p>0.05; Figure 2).
Grading  of  lens  opacification:  The  onset  of  cataract  was
observed  after  two  weeks  by  slit  lamp  examination.  The
median calculation of lens opacity was presented in Table 2.
All the lenses in group I appeared to be clear and normal
throughout the experimental period whereas after four weeks,
only 30% of the lenses were in grade 1, 60% in grade 2, 10%
in grade 3 of cataract formation, and none of them were clear
(grade 0; Table 2) in group V, the untreated diabetic rats.
However, on the fourth week, more than 50% of the lenses
were clear in groups II and IV whereas in group V, most of
the lenses were in grade 2 and only a few were clear (p<0.05;
Table 2). After five weeks, lens opacification became worse
in groups II-V with no significant difference between the
diabetic  groups,  treated  and  untreated  (p>0.05;  Table  2).
Figure 2. Changes of rat’s bodyweight before and after the injection
of streptozotocin. Data are the average of results in all the animals
in a given group. The weights of the normal rats were significantly
different from the four diabetic groups (p<0.05), and there were no
significant differences between the four diabetic groups (p>0.05) at
any time.
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drops delayed progression of hyperglycemia-induced cataract
at the earlier period. At the end of 11 weeks, most of the lenses
(65%) in groups II-V showed development of mature cataract
(grade 7: nuclear cataract with whole lens opacities; Table 2).
Remarkably, the grade of lens opacification in groups II
and IV almost stay clear before four weeks while in group V,
the lens opacification progressed almost to grade 2 after three
weeks (Table 2). This observation indicates that NAC and
GSH-EE can delay the onset of diabetic cataract, but they
failed to delay or reverse the severity of cataract at later stages.
Activity of enzymes: The water-soluble protein concentration
was unchanged in various grades of lens opacification (Table
3). A decrease of thiol content was found in the lens of diabetic
rats  (groups  II-V)  at  different  stages  after  STZ  injection
(p<0.05; Table 4). The level of thiols (from GSH and protein)
in the lens of diabetic rats decreased to about 50% of the level
of the normal controls at each different stage while the content
of thiol slightly decreased with time in the normal group.
Surprisingly, NAC and GSH-EE enhanced thiol levels by
about  12%–18%  compared  to  the  untreated  group  on  the
fourth week (Table 4), but it was statistically insignificant.
The activity of GR decreased by 20% in the diabetic rats at all
stages, but this difference was not statistically significant. No
change  of  GR  activity  was  observed  during  cataract
progression in the diabetic rats (Table 5).
The activity of CAT was significantly lower in diabetic
rats than in the normal rats (p<0.05; Table 6). In the present
TABLE 1. THE CHANGES OF BLOOD GLUCOSE AFTER INJECTION OF STREPTOZOTOCIN.
Group n 72 h 4 weeks 8 weeks 13 weeks p
I 10 6.99±0.42 7.01±0.46 6.13±0.35 6.20±0.73 0.470
II 18 29.18±5.80a 28.73±3.23a 31.46±4.32a 29.39±9.16a 0.341
III 19 28.94±5.53a 27.51±3.01a 31.90±2.20a 31.76±1.69a 0.375
IV 19 28.13±2.68a 29.12±3.05a 31.93±1.99a 31.20±1.87a 0.251
V 19 29.43±5.23a 28.61±5.68a 32.00±1.41a 29.48±7.63a 0.840
Each value is the mean±SD of results in all the animals in a given group. “a” denotes that p<0.05 when comparing the normal
group (group I) with the four diabetic groups (group II-V). There were no statistically significant differences between the four
diabetic groups. In the column headed “p” the value represents the comparison between four different times. Group I: normal;
II: NAC-treated (0.1 mg/ml); III: NAC-treated (0.5 mg/ml); IV: GSH-EE-treated (1 mg/ml); V: untreated diabetic.
TABLE 2. THE EFFECT OF NAC AND GSH-EE ON STREPTOZOTOCIN-INDUCED LENS OPACITY.
Group 3 week 4 week 5 week 6 week 7 week 8 week 9 week 10 week 11 week 12 week 13 week
I 00000000000
II 0 0* 223456777
III 01234456677
IV 0 0# 224455677
V 12234556677
Values are expressed as medians. Median representation: 0, clear; 1, clear nuclear with wide sutures; 2, slight dense nuclear
with opacities radiating from sutures; 3, dense nuclear without clefts; 4, dense nuclear with clefts; 5, nuclear cataract with clefts;
6, nuclear cataract with dense radial opacities; and 7, nuclear cataract with whole lens opacities. Statistical analyses were
performed by using Wilcoxon rank sum test. Note: The asterisk denotes that p=0.023 (group II compared with group V on the
fourth week). The asterisk denotes that p=0.031 (group IV compared with group V on the fourth week). Group I: normal; II:
NAC-treated (0.1 mg/ml); III: NAC-treated (0.5 mg/ml); IV: GSH-EE-treated (1 mg/ml); V: untreated diabetic.
TABLE 3. THE WATER-SOLUBLE PROTEIN IN VARIOUS GRADE OF LENS OPACIFICATION.
Time Group I Group II Group III Group IV Group V
4th week 5.29±0.5 4.35±0.5 4.32±0.9 5.14±0.4 4.99±0.5
8th week 5.03±0.3 4.01±0.5 4.12±0.9 4.36±0.3 4.40±0.3
13th week 4.73±0.5 4.37±0.7 4.30±0.8 4.21±0.6 4.33±0.8
The data are the mean±SD (group I, n=6 lenses; other groups, n=12 lenses at each time). The water-soluble protein is expressed
as g/l. There were no significant differences during all the five groups at various grade of lens opacification. Group I: normal;
II: NAC-treated (0.1 mg/ml); III: NAC-treated (0.5 mg/ml); IV: GSH-EE-treated (1 mg/ml); V: untreated diabetic.
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866study, we observed a loss of approximately 40% of lens CAT
activity in diabetic rats on the fourth week, 42% on the eighth
week, and 55% on 13th week (p<0.05). NAC and GSH-EE
treatment resulted in a slight increase in CAT activity at the
earlier cataract stages (Table 6).
A rise of protein glycation was found in diabetic groups
with statistically significant differences (p<0.05; Table 7). No
effects of NAC and GSH-EE drops on the level of glycation
were noted (Table 7).
TABLE 4. THE EFFECT OF NAC AND GSH-EE ON THE THIOL CONTENT OF RAT LENSES.
Time Group I Group II Group III Group IV Group V
4th week 118.2±22.04 80.50±21.21 78.31±19.10 76.32±20.02 68.44±23.45
8th week 115.1±19.57 52.50±20.11 54.43±19.60 52.62±22.82 50.27±24.18
13th week 105.68±19.06 40.50±19.07 39.59±21.61 40.60±20.12 40.54±18.17
The data are the mean±SD (group I, n=6 lenses; other groups, n=12 lenses at each time). The total thiol is expressed as milligrams
per gram protein. No significant differences were observed among the four diabetic groups (group II-V) at any given stage.
Group I: normal; II: NAC-treated (0.1 mg/ml); III: NAC-treated (0.5 mg/ml); IV: GSH-EE-treated (1 mg/ml); V: untreated
diabetic.
TABLE 5. THE EFFECT OF NAC AND GSH-EE ON THE ACTIVITY OF GR IN RAT LENSES.
Time Group I Group II Group III Group IV Group V
4th week 6.76±2.60 6.01±2.75 5.86±2.65 6.02±2.52 5.41±2.58
8th week 6.70±0.70 5.31±2.37 5.77±2.94 5.65±3.31 5.29±2.85
13th week 6.49±2.44 5.01±2.13 5.20±2.52 5.29±2.73 5.11±2.72
The data are the mean±SD (group I, n=6 lenses; other groups, n=12 lenses at each time). The activity of GR is expressed as
μmol per gram protein. At all stages, the mean values for all diabetic groups were less than the normal group, but there were no
significant differences between all five groups at various stages. Group I: normal; II: NAC-treated (0.1 mg/ml); III: NAC-treated
(0.5 mg/ml); IV: GSH-EE-treated (1 mg/ml); V: untreated diabetic.
TABLE 6. THE EFFECT OF NAC AND GSH-EE ON THE ACTIVITY OF CAT IN RAT LENSES.
Time Group I Group II Group III Group IV Group V
4th week 55.58±24.22 36.56±7.90 37.40±5.28 34.80±13.63 33.02±7.45
8th week 50.24±26.34 29.51±14.90 30.07±7.28 29.73±6.35 29.04±10.36
13th week 46.29±11.32 21.51±7.92 23.07±13.35 22.79±9.37 20.55±10.37
The data are the mean±SD (group I, n=6 lenses; other groups, n=12 lenses at each time). The activity of CAT is expressed as
μmol per gram protein. There were no significant differences between the four diabetic groups (group II-V) at any given stage.
A statistically significant difference was observed between the normal group (group I) and the untreated group (group V) in
various stages (p<0.05). Group I: normal; II: NAC-treated (0.1 mg/ml); III: NAC-treated (0.5 mg/ml); IV: GSH-EE-treated
(1mg/ml); V: untreated diabetic.
TABLE 7. THE EFFECT OF NAC AND GSH-EE ON THE CONTENT OF GLYCATION IN RAT LENSES.
Time Group I Group II Group III Group IV Group V
4th week 4.10±0.21 4.80±0.34 4.77±0.25 4.81±0.23 4.89±0.29
8th week 4.33±0.29 5.61±0.34 5.00±0.25 5.22±0.25 5.25±0.28
13th week 4.87±0.23 5.77±0.37 5.91±0.30 5.82±0.27 5.90±0.31
The data are the mean±SD (group I, n=6 lenses; other groups, n=12 lenses at each time). The content of glycation is expressed
as mmoles HMF per mole protein. There were no significant differences between the four diabetic groups (group II-V) at any
given stage. The statistically significant difference was observed between the normal group (group I) and the untreated group
(group V) in various stages (p<0.05). Group I: normal; II: NAC-treated (0.1 mg/ml); III: NAC-treated (0.5 mg/ml); IV: GSH-
EE-treated (1 mg/ml); V: untreated diabetic.
Molecular Vision 2008; 14:862-870 <http://www.molvis.org/molvis/v14/a103> © 2008 Molecular Vision
867DISCUSSION
Diabetic lenses in both humans and hyperglycemic animals
were shown to be the subject of elevated oxidative stress [5,
35,38]. Many drugs have been used for anticataract research
in animals [1,14,39], and some have proved effective in the
prevention of lens opacity. GSH is important to maintain lens
proteins in a reduced state, and a healthy lens utilizes its
various antioxidants and oxidation defense enzymes to protect
itself against oxidation [1,40,41].
GSH itself is not membrane permeable thus it is not
effectively transported into cells [42]. The NAC and GSH
ester have acted as GSH precursors to regulate the content of
GSH in tissues and cells [43,44]. NAC and GSH esters provide
the direct and convenient means available for increasing the
intracellular GSH concentration of many tissues and cell types
[13,22].
In the present study, NAC and GSH-EE drops were used
for the first time in STZ-induced diabetic cataract and showed
an inhibition of early cataract. The drugs for NAC and GSH-
EE  are  liposoluble  substrates,  which  can  permeate  across
biomembranes [45,46]. The administration route of previous
studies in vivo and in vitro were performed intraperitoneally
or taken orally, and both of these were performed with some
complications  [18,27-29].  This  study  investigated  the
feasibility and the efficacy of NAC and GSH-EE drops in
diabetic cataract. During the whole process, there were no
remarkable stimulating reactions on the eyes. The drops are
proved to be better modalities than oral treatment for safety
and convenience. The present concentrations of eyes drops
were based on previous studies [15,28,47]. According to our
previous studies, we chose the dose of eye drops consistent
with the injected dose, and the volume dose was increased
along with the increase of rats’ bodyweight. To overcome the
limitation of the volume applied by a single dosage to rat eyes,
we increased the frequency of administration to sustain the
volume dose. Therefore, we made 0.1 mg/ml (0.01%) and
0.5 mg/ml (0.05%) NAC drop solutions and applied them to
the rats’ eyes three times a day, and we made 1 mg/ml (0.1%)
GSH-EE drops solution and applied them twice daily.
NAC and GSH-EE slightly inhibited the progression of
diabetic cataract at the earlier stages. Slit lamp evaluation
revealed the prevention of lens opacification, even though this
function was statistically significant only at a very early stage
(the  fourth  week  after  injection).  However,  there  was  no
statistically significant difference in the progression of lens
opacification between the two drugs at later stages or in the
two different concentrations of the NAC-treated groups.
NAC and GSH-EE appeared to enhance the content of
thiol (from GSH and protein) in the treated groups compared
with the untreated group at every stage, but the differences
were statistically insignificant. The difference in thiol content
between the treated groups and the untreated group is more
obvious in the fourth week than in the 8th and 13th week. This
may be due to the GSH supplement being unable to cope with
the  large  changes  in  mature  cataract  lenses.  Among  the
benefits of GSH, it can decrease the rate of glycation [48].
NAC and GSH-EE did not prevent GR and CAT from
decreasing  in  the  treated  groups.  This  may  be  due  to
permeability  and  an  inability  to  achieve  effective  drug
concentrations, the level of blood glucose being too high for
NAC and GSH-EE against diabetic cataract, or the fact that
the  inactivation  of  these  enzymes  is  not  related  to  the
concentration of GSH. Consistent with the results of others
[49],  the  activity  of  GR  was  relatively  unchanged  during
cataract progression in the diabetic rats. Glucose binds non-
enzymically to this enzyme and inhibits it [37]. The activity
of CAT in the lens may similarly be affected, resulting in a
decrease in GSH. The early loss of GSH in diabetic cataract
may result from the inactivation of various enzymes including
CAT and GR, which have a role in maintaining GSH levels.
In hyperglycemia, the levels of reactive oxygen species (ROS)
in the lens rise. Enzymes that protect against oxidation may
be inactivated and rendered ineffective by either glycation or
oxidation. The data indicates that the beneficial effects of
NAC and GSH-EE do not seem to be associated with GR and
CAT activities.
Our results demonstrated an increase in glycation levels
in  addition  to  a  decrease  in  certain  antioxidant  enzyme
activities. This suggests NAC and GSH-EE as antioxidants
are ineffective in inhibiting glycation at such high levels of
hyperglycemia. It has been suggested that glycation of lens
crystallins may cause conformational changes that result in
the  exposure  of  thiol  groups  to  oxidation  and  cross-link
formation [1,38,50]. Glycation, which causes the aggregation
of lens crystallins that produce the high molecular weight
material responsible for opacification, was demonstrated by
animal studies [38,51].
The biochemical and morphologic changes in the NAC-
treated groups were similar to the NAC-treated groups with
two different concentrations were similar to the changes in the
GSH-EE-treated group. The two drugs, administered before
the STZ injection, resulted in a significant prevention of lens
opacification at an early stage. NAC and GSH-EE as thiol-
containing  antioxidants  can  penetrate  freely  into  the  lens,
increasing  the  level  of  GSH  [17],  and  having  benefits
attributed to the participation of the SH group of GSH in the
diabetic lens which inhibits oxidative stress in the lens [39].
There was no obvious dose-dependent effect in the two NAC-
treated groups, which may be due to the similarity of the two
concentrations or the limitations in penetrating into the lens.
In conclusion, the study showed NAC and GSH-EE delay
the progression of lens opacification in diabetic rats in the
earlier stage. They may serve as a precursor for glutathione
biosynthesis, increase the levels of GSH, inhibit oxidative
insult of crystallins and antioxidant enzymes, and thus protect
the lens transparency. Therefore, research on the mechanism
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868of NAC and GSH-EE provides an important experimental
base for the drug treatment of cataract.
It remains to be determined whether NAC and GSH esters
are limited in their transport into the eyes. These derivatives
of GSH also need to be investigated with respect to their
transport properties. The present and previous findings, which
support the view that cataracts are produced by oxidation and
glycation  of  lens  proteins,  suggest  that  procedures  that
increase  lens  GSH  levels  would  protect  against  the
development of cataract.
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